糖肾康饮治疗早期糖尿病肾病的临床疗效观察及对VEGF的影响
发布时间：2018-08-02 13:00
【摘要】：目的:通过观察糖肾康饮治疗早期糖尿病肾病的疗效及对血清VEGF表达水平的影响,客观评价糖肾康饮的临床疗效,并探讨其可能作用机制。方法:选取在2016年1月至2017年1月期间于黑龙江中医药大学附属第一医院内分泌门诊诊断为早期糖尿病肾病,中医辨证为气阴两虚兼瘀证的患者80例,随机分为治疗组和对照组各40例。全部患者予基础治疗,包括糖尿病教育、饮食调摄、运动疗法、皮下注射胰岛素控制血糖、厄贝沙坦75mg日一次口服,治疗组在此基础上加服糖肾康饮。本次临床观察持续8周,观察治疗前后患者UAER、血清VEGF、血脂及中医证候积分的变化情况。结果:1.经8周治疗后,治疗组中医证侯积分改善情况显著优于对照组(P0.05),治疗组和对照组中医证候总有效率分别为82.0%和36.8%,治疗组中医证候疗效显著优于对照组(P0.05)。2.经8周治疗后,治疗组总有效率87.2%,对照组总有效率55.3%,治疗组临床效果显著优于对照组(P0.05)。3.经8周治疗后,两组血脂相关指标均较治疗前改善(P0.05),组间差值比较显示治疗组改善TC、TG、LDL-C、HDL-C程度显著优于对照组(P0.05)。4.经8周治疗后,两组UAER均较治疗前显著降低(P0.05);组间差值比较显示治疗组降低UAER显著优于对照组(P0.05)。5.经8周治疗后,两组血清VEGF均显著减低(P0.05),组间差值比较显示治疗组降低血清VEGF显著优于对照组(P0.05)。结论:1.糖肾康饮可有效降低早期糖尿病肾病患者UAER水平,减轻肾损伤程度;2.糖肾康饮可改善早期糖尿病肾病气阴两虚兼瘀证患者中医临床症状;3.糖肾康饮可降低患者TC、TG、LDL-C水平,具有升高患者HDL-C的作用,可改善脂代谢紊乱;4.糖肾康饮可能通过减少患者血清VEGF的表达起到延缓DN进展的作用。
[Abstract]:Objective: to evaluate the clinical efficacy of Tangshenkang decoction in the treatment of early diabetic nephropathy and to explore its possible mechanism by observing the effect of Tangshenkang decoction on the expression of serum VEGF. Methods: from January 2016 to January 2017, 80 patients were diagnosed as early diabetic nephropathy in the endocrine clinic of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. They were randomly divided into treatment group (n = 40) and control group (n = 40). All patients were treated with basic treatment, including diabetes education, diet adjustment, exercise therapy, subcutaneous injection of insulin to control blood glucose, irbesartan 75mg once a day, the treatment group on the basis of taking Tangshenkang decoction. The clinical observation lasted 8 weeks. The changes of UAER, serum VEGF, blood lipid and TCM syndromes were observed before and after treatment. The result is 1: 1. After 8 weeks treatment, the improvement of TCM syndrome score in treatment group was significantly better than that in control group (P0.05). The total effective rate of TCM syndrome in treatment group and control group were 82.0% and 36.8%, respectively. The curative effect of TCM syndrome in treatment group was significantly better than that in control group (P0.05). 2. After 8 weeks of treatment, the total effective rate of the treatment group was 87.2 and the total effective rate of the control group was 55.3. The clinical effect of the treatment group was significantly better than that of the control group (P0.05). 3. After 8 weeks of treatment, the serum lipids in both groups were improved compared with those before treatment (P0.05), and the difference between the two groups showed that the degree of HDL-C in the treatment group was significantly better than that in the control group (P0.05). 4. After 8 weeks of treatment, the UAER in both groups was significantly lower than that before treatment (P0.05), and the difference between groups showed that the decrease of UAER in the treatment group was significantly better than that in the control group (P0.05). After 8 weeks of treatment, the serum VEGF in both groups was significantly decreased (P0.05), and the difference between the two groups showed that the decrease of serum VEGF in the treatment group was significantly better than that in the control group (P0.05). Conclusion 1. Tangshenkang decoction can effectively reduce the level of UAER in patients with early diabetic nephropathy and alleviate the severity of renal injury. Tangshenkang decoction can improve the clinical symptoms of early diabetic nephropathy patients with deficiency of qi and yin and blood stasis. Tangshenkang decoction can reduce the LDL-C level of TCU TGG, increase the level of HDL-C in patients, and improve lipid metabolism disorder 4. 5%. Tangshenkang decoction may delay the progression of DN by reducing the expression of serum VEGF.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
本文编号：2159516
[Abstract]:Objective: to evaluate the clinical efficacy of Tangshenkang decoction in the treatment of early diabetic nephropathy and to explore its possible mechanism by observing the effect of Tangshenkang decoction on the expression of serum VEGF. Methods: from January 2016 to January 2017, 80 patients were diagnosed as early diabetic nephropathy in the endocrine clinic of the first affiliated Hospital of Heilongjiang University of traditional Chinese Medicine. They were randomly divided into treatment group (n = 40) and control group (n = 40). All patients were treated with basic treatment, including diabetes education, diet adjustment, exercise therapy, subcutaneous injection of insulin to control blood glucose, irbesartan 75mg once a day, the treatment group on the basis of taking Tangshenkang decoction. The clinical observation lasted 8 weeks. The changes of UAER, serum VEGF, blood lipid and TCM syndromes were observed before and after treatment. The result is 1: 1. After 8 weeks treatment, the improvement of TCM syndrome score in treatment group was significantly better than that in control group (P0.05). The total effective rate of TCM syndrome in treatment group and control group were 82.0% and 36.8%, respectively. The curative effect of TCM syndrome in treatment group was significantly better than that in control group (P0.05). 2. After 8 weeks of treatment, the total effective rate of the treatment group was 87.2 and the total effective rate of the control group was 55.3. The clinical effect of the treatment group was significantly better than that of the control group (P0.05). 3. After 8 weeks of treatment, the serum lipids in both groups were improved compared with those before treatment (P0.05), and the difference between the two groups showed that the degree of HDL-C in the treatment group was significantly better than that in the control group (P0.05). 4. After 8 weeks of treatment, the UAER in both groups was significantly lower than that before treatment (P0.05), and the difference between groups showed that the decrease of UAER in the treatment group was significantly better than that in the control group (P0.05). After 8 weeks of treatment, the serum VEGF in both groups was significantly decreased (P0.05), and the difference between the two groups showed that the decrease of serum VEGF in the treatment group was significantly better than that in the control group (P0.05). Conclusion 1. Tangshenkang decoction can effectively reduce the level of UAER in patients with early diabetic nephropathy and alleviate the severity of renal injury. Tangshenkang decoction can improve the clinical symptoms of early diabetic nephropathy patients with deficiency of qi and yin and blood stasis. Tangshenkang decoction can reduce the LDL-C level of TCU TGG, increase the level of HDL-C in patients, and improve lipid metabolism disorder 4. 5%. Tangshenkang decoction may delay the progression of DN by reducing the expression of serum VEGF.
【学位授予单位】：黑龙江中医药大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R259
【参考文献】
相关期刊论文 前10条
1 谢灯飘;阮诗玮;;阮诗玮教授治疗肝肾阴虚型糖尿病肾病临床经验[J];亚太传统医药;2017年04期
2 薛青;;益肾泄浊方治疗糖尿病肾病气阴两虚、肾络瘀阻证临床研究[J];中医学报;2017年02期
3 王艺;彭国庆;江新泉;宋文刚;张秋玲;王庆宝;李文;;黄精多糖对糖尿病大鼠模型的保护机制研究[J];中医药导报;2017年02期
4 孟加宁;姚源璋;;姚源璋教授治疗糖尿病肾病经验介绍[J];中国中西医结合肾病杂志;2017年01期
5 王东;李阳欣;李敬林;;从脾肾亏虚论治糖尿病肾病[J];辽宁中医杂志;2017年01期
6 王鸿;马志红;张美莲;田俊萍;;2型糖尿病患者血尿酸与肾脏损害的相关性分析[J];山西医药杂志;2017年01期
7 胡钢;;李果烈治疗早期糖尿病肾病经验[J];河南中医;2017年01期
8 张舒;查敏;严倩华;叶丽芳;黄莉吉;余江毅;;芪葵方对糖尿病肾病患者血糖、血脂、肾功能以及尿足细胞相关蛋白的影响研究[J];中药材;2016年10期
9 刘洪;熊维建;郑新;;国医大师郑新论治糖尿病肾病的学术思想和临证经验[J];中华中医药杂志;2016年11期
10 殷芳;杨宇峰;石岩;;糖尿病肾病中医病因病机理论框架结构研究[J];辽宁中医药大学学报;2016年11期
，本文编号：2159516
本文链接：https://www.wllwen.com/zhongyixuelunwen/2159516.html
最近更新
教材专著
